Dr Meric-Bernstam on the Use of Trastuzumab Deruxtecan in HER2+ Solid Tumors
Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of trastuzumab deruxtecan in difficult-to-treat HER2-positive solid tumors.
Source: onclive.com
Page 8 - Phasei Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Program Today - Breaking & Trending Today
Trastuzumab Deruxtecan Elicits Response in Difficult-To-Treat HER2+ Solid Tumors
Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.
Source: onclive.com
Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer
Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.
Source: onclive.com
Simple Hysterectomy Deemed Noninferior to Radical Version in Low-Risk, Early-Stage Cervical Cancer
Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.
Source: targetedonc.com
Simple Hysterectomy 'the New Standard' for Low-Risk, Early Cervical Cancer
Results of the Canadian Cancer Trials Group CX.5/SHAPE trial could lead to surgical de-escalation among patients with cervical cancer.
Source: curetoday.com